Haemonetics Corporation

HAE

$102.85

-0.07%

N/A-$0.07

Healthcare

Medical - Devices

NYSE

Active Trading

Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood ...

C-Suite Executives

(0)

The C-suite executives form a cohesive leadership team driving the company's financial strategy and innovation.

Key Team Members

No executives available for this level

Founder / CEO

C-Level

Board

Director / Board

Other

Key Executives

Name	Title	Compensation	Gender	Year Born	Status
Christopher A. Simon	Chief Executive Officer, President & Director	USD 2,977,746		1964	Active
Frank W. Chan	Executive Vice President & Chief Operating Officer	USD 1,463,714		1970	Active
James C. D'Arecca	Chief Financial Officer, Executive Vice President & Financial Officer	USD 1,281,546		1971	Active
Michelle L. Basil	Executive Vice President, General Counsel & Secretary	USD 1,185,269		1973	Active
Roy Galvin	Executive Vice President & Chief Commercial Officer	USD 1,165,983		1970	Active
Josh Gitelson	Senior Director of Global Communications	—		—	Active
Rajeev Varma	Senior Vice President of Strategy & Corporate Development	—		—	Active
Olga Guyette	VP of IR & Treasury	—		—	Active
Farris Maryanne Maunsell	Vice President, Chief Accounting Officer & Principal Accounting Officer	—		1976	Active
Laurie A. Miller	Senior Vice President & Chief Human Resources Officer	—		1974	Active
Jan Hartmann	Senior Vice President & Chief Medical Officer	—	—	—	Active
David J. Wilson	President of Plasma Business Unit	—		1968	Active

Executive Compensation

(deduped by latest filing date per person-year)

Filing Date	Year	Name	Position	Level	Salary	Bonus	Stock Award	Option Award	Incentive	Other	Total
2026-06-09	2026	Christopher A. Simon	President President and Chief Chief Executive Officer	Founder / CEO	$1.10M	$0	$7.56M	$1.50M	$1.83M	$43.49K	$12.04M
2026-06-09	2026	James C. D'Arecca Executive	Vice Vice President President, Chief Chief Financial Officer	C-Level	$603.70K	$0	$1.84M	$499.99K	$648.86K	$28.99K	$3.62M
2026-06-09	2026	Michelle L. Basil Executive	Vice Vice President President, General General Counsel	C-Level	$558.78K	$0	$1.75M	$474.98K	$599.77K	$26.73K	$3.41M
2026-06-09	2026	Frank W. Chan Executive	Vice Vice President President, Chief Chief Operating Officer	C-Level	$518.26K	$350.00K	$1.47M	$400.00K	$574.06K	$21.39K	$3.34M
2026-06-09	2026	Roy Galvin Executive	Vice Vice President President, Chief Chief Commercial Officer	C-Level	$550.21K	$0	$1.47M	$400.00K	$586.96K	$28.82K	$3.04M
2026-06-09	2025	Christopher A. Simon	President President and Chief Chief Executive Officer	Founder / CEO	$1.10M	$0	$7.03M	$1.40M	$1.13M	$64.22K	$10.72M
2026-06-09	2025	James C. D'Arecca Executive	Vice Vice President President, Chief Chief Financial Officer	C-Level	$575.58K	$0	$1.56M	$424.96K	$381.87K	$29.58K	$2.98M
2026-06-09	2025	Michelle L. Basil Executive	Vice Vice President President, General General Counsel	C-Level	$537.87K	$0	$1.47M	$400.00K	$356.24K	$28.71K	$2.79M
2026-06-09	2025	Roy Galvin Executive	Vice Vice President President, Chief Chief Commercial Officer	C-Level	$490.15K	$0	$1.01M	$274.99K	$378.26K	$41.20K	$2.20M
2026-06-09	2024	Christopher A. Simon	President President and Chief Chief Executive Officer	Founder / CEO	$1.09M	$0	$6.32M	$1.62M	$2.45M	$63.26K	$11.55M
2026-06-09	2024	James C. D'Arecca Executive	Vice Vice President President, Chief Chief Financial Officer	C-Level	$548.21K	$0	$1.46M	$374.98K	$735.92K	$28.45K	$3.15M
2026-06-09	2024	Michelle L. Basil Executive	Vice Vice President President, General General Counsel	C-Level	$517.19K	$0	$1.46M	$374.98K	$694.55K	$26.18K	$3.07M

Total Compensation Trend

Sum of disclosed compensation by year (USD million)

Key Roles Compensation Lines

Top founder/C-level executives over time (USD million)

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer